Evidence map›Paper›PMID 40299892›Full record

ReviewESC heart failure2025

Role for inflammatory markers in predicting right ventricular failure in mechanical assist device recipients.

Abdul-Fatawu Osman, Shane S Scott, Ebubechukwu O Ezeh, Evans Osuji, Israel O Ailemen, Mohamed H Derbala, Salil Kumar, Asvin M Ganapathi, Daniel B Sims, Ashrith Guha and 2 more

Abstract readReview
In one paragraph

Review in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abdul-Fatawu OsmanDepartment of Internal Medicine, Michigan State University, Lansing, Michigan, USA.
Shane S ScottMedical Scientist Training Program, Biomedical Sciences Graduate Program, Ohio State University, Columbus, Ohio, USA.
Ebubechukwu O EzehDepartment of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, Huntington, West Virginia, USA.
Evans OsujiDavis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA.
Israel O AilemenDavis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA.
Mohamed H DerbalaDavis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA.
Salil KumarHouston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA.
Asvin M GanapathiDivision of Cardiac Surgery, Department of Surgery, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Daniel B SimsDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Ashrith GuhaDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Bryan A WhitsonDivision of Cardiac Surgery, Department of Surgery, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Sakima A SmithDavis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-3887-9180

Funding

Training To Provide the Knowledge, Skills, and Culture To the Next Generation of Cardiovascular ScientistsT32HL134616 · NHLBI · OHIO STATE UNIVERSITY · PI Brandon J Biesiadecki, Jill A Rafael-Fortney · 2017 to 2026
$2.6M
Defining Novel Cardiovascular Mechanisms For TKI Induced ExcitabilityR01HL160590 · NHLBI · OHIO STATE UNIVERSITY · PI Sakima Ahmad Smith · 2022 to 2026
$2.0M
National Institute of Health FrickFundGF483501(SAS)National Institute of Health R01HL160590National Institute of Health T32HL134616NHLBI NIH HHS R01 HL160590NHLBI NIH HHS T32 HL134616
6 · The paper itself

Abstract

Right ventricular failure (RVF) is a common complication following left ventricular assist device (LVAD) implantation and increases patient morbidity and mortality. Due to the complex and limited understanding of RVF pathophysiology, efforts to prognosticate RVF after LVAD have been challenging. To fill the gaps, current efforts have been focused on identifying molecular drivers and physiological mechanisms of right ventricular dysfunction in this population. Recent work suggests that pro-inflammatory and oxidative stress pathways contribute to the development and progression of RVF post-LVAD, and elevation of inflammatory indices have been correlated with poor prognosis. Current prediction models are limited and performed only modestly in validation studies and do not include immunologic and molecular parameters, which could enhance pre-operative risk stratification towards reducing post-operative burden of RVF post-LVAD. In this review, we identified and summarized clinically relevant molecular and inflammatory markers of RVF and RVF following LVAD placement. Correlating these markers with current haemodynamic and echocardiographic parameters provides an avenue to reduce RVF after LVAD.

Indexed as

Heart-Assist DevicesHeart FailureInflammationVentricular Dysfunction, RightBiomarkersHumansPrognosisBiomarkersadverse remodellingbiomarkersinflammationleft ventricular assist device (LVAD)prediction risk scoresreactive oxygen species (ROS)right ventricular failure (RVF)

Identifiers

PMID40299892
PMCPMC12287856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.